2021
DOI: 10.1002/lt.26272
|View full text |Cite
|
Sign up to set email alerts
|

Monitoring of Donor‐Derived Cell‐Free DNA by Short Tandem Repeats: Concentration of Total Cell‐Free DNA and Fragment Size for Acute Rejection Risk Assessment in Liver Transplantation

Abstract: Monitoring of graft function is essential during the first months after liver transplantation (LT), but current liver function tests (LFTs) lack the specificity and sensitivity to ensure an efficient diagnosis of acute rejection (AR). Recently, donor-derived cell-free DNA (ddcfDNA) has emerged as a noninvasive biomarker to assess graft integrity. This study evaluated the feasibility of measuring the ddcfDNA through short tandem repeat (STR) analysis by quantitative fluorescent-polymerase chain reaction (QF-PCR… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
19
0
3

Year Published

2022
2022
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 22 publications
(24 citation statements)
references
References 30 publications
2
19
0
3
Order By: Relevance
“…Although several studies could show excellent diagnostic accuracy of dd‐cfDNA for the detection of acute biopsy proven rejection, for example, in contrast to nonrejection graft hepatitis, [ 15,17–21 ] this is the first study evaluating the diagnostic accuracy of dd‐cfDNA as a noninvasive biomarker for subclinical liver graft injury. The threshold of liver enzymes applied here to define subclinical graft injury is derived from observations that liver enzyme elevation above 2 × ULN but not the presence of rejection pattern in early svLBx is associated with a reduced prognosis after LT.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Although several studies could show excellent diagnostic accuracy of dd‐cfDNA for the detection of acute biopsy proven rejection, for example, in contrast to nonrejection graft hepatitis, [ 15,17–21 ] this is the first study evaluating the diagnostic accuracy of dd‐cfDNA as a noninvasive biomarker for subclinical liver graft injury. The threshold of liver enzymes applied here to define subclinical graft injury is derived from observations that liver enzyme elevation above 2 × ULN but not the presence of rejection pattern in early svLBx is associated with a reduced prognosis after LT.…”
Section: Discussionmentioning
confidence: 99%
“…[ 17,18 ] However, previous studies are limited to the first year after LT or did not assess subclinical liver graft injuries. [ 16,19–21 ]…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…A recent study aimed to evaluate the feasibility of measuring dd-cfDNA through short tandem repeats analysis by quantitative fluorescent-PCR and, to assess the role of the concentration and fragment size of total cfDNA as biomarkers of acute rejection. 110 Short tandem repeat amplification by quantitative fluorescent-PCR may be an alternative, easily implementable, strategy for rapid dd-cfDNA quantification in clinical laboratories. The results of this pilot study indicate that dd-cfDNA increases very early, even 1-2 weeks before the diagnosis of acute rejection, so it could be useful as a prognostic biomarker to improve patient risk stratification.…”
Section: Mirnas As Markers Of Injurymentioning
confidence: 99%
“…Moreover, elevation of dd-cfDNA levels may occur 1-2 weeks before diagnosis of AR. [9][10][11] Here we report the utility of dd-cfDNA in a case of GVHD after LT.…”
Section: Introductionmentioning
confidence: 97%